Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

FDA:s rådgivande vaccinmöte inställt – utan förklaring

Ett årligt möte mellan FDA och deras rådgivande vaccinkommitté ställs in.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Collaboration in laboratory automation

The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...

Uppsala-based company wins important patent dispute – but the decision is subject to appeal

A US district court has ruled in favour of Orexo in a dispute over the patent protecting the Swedish company’s drug Zubsolv, developed for treating patients wit...

"Unclear proposal from the EU Commission on how to solve the MDR challenges"

Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...

Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute

Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

Gröna satsningar ger klirr i kassan för svenska tillverkare

Allt fler svenska medelstora tillverkare ser hållbarhet som en självklar del av affären – och inte bara för att det är rätt väg framåt ur ett miljöperspektiv. E...

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

Caroline Leksell Cooke ny chef på Elekta

Elekta har rekryterat Caroline Leksell Cooke till ny Senior Vice President och Head of Neuro Solutions. Hon börjar sin nya tjänst den 1 november.

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

Nanexa develops depot formulation of the diabetes and obesity drug Saxenda

Uppsala-based company Nanexa has signed an agreement with a German contract research company to start a clinical study with a monthly depot of liraglutide. The ...

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

Cytel Sweden

“Unfortunately, we are not strong when it comes to conducting clinical trials”

The number of company-initiated clinical trials conducted in Sweden has been declining in recent years. In mid-March, a government inquiry was presented that ai...

A+ Science AB

Olika bud om distansarbete – ”Vi ber vår personal att komma tillbaka till kontoret”

Hur viktigt är det för life science-bolagen att erbjuda distansarbete? Den frågan väckte debatt och fick många olika svar vid en paneldiskussion om talangrekryt...